Navigation Links
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy

in all treatment groups. No clinically significant changes in glucose or lipids were seen with nebivolol monotherapy during the study. -- "Addition of the Beta-Blocker Nebivolol to Ongoing Therapy in the Management of Mild-to-Moderate Hypertension" by Alan H. Gradman, MD, Chief, Division of Cardiovascular Diseases, The Western Pennsylvania Hospital. [Poster Presentation, P-383: Monday, May 21 from 12 pm to 1 pm (Riverside Hall)] The blood pressure lowering effects and tolerability of nebivolol added to ongoing antihypertensive therapy in patients was evaluated in this 12-week, randomized, double-blind, placebo-controlled study (n=669). Results indicate that, by comparison to placebo, nebivolol incrementally lowers blood pressure in mild to moderate hypertensive patients when added to ongoing antihypertensive therapy consisting of one or two medications from the following classes: ACE inhibitors, ARBs, or diuretics, with an incidence of reported adverse events similar to placebo. -- "Efficacy of the Novel Beta-blocker Nebivolol in Obese and Non-Obese Hypertensive Patients" by James R. Sowers, MD, Professor of Medicine and Physiology, Director Diabetes and Cardiovascular Center, University of Missouri. [Poster Presentation, P-442: Monday, May 21 from 12 pm to 1 pm (Riverside Hall)] The blood pressure lowering effects of nebivolol was compared in non- obese and obese hypertensive patients, a population that typically has a poorer response to treatment and an increased need for multiple medications. The pooled analysis of three randomized, double-blind, placebo-controlled trials of similar design was stratified by patient obesity status (BMI greater than or equal to 30 kg/m2) at baseline (obese, n=878; non-obese, n=1136). Results suggest that once-
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:7/27/2015)... Varian Medical Systems UK Ltd announced today it ... and service two new national NHS proton therapy centers in ... proton therapy system. Earlier this year, Varian announced that ... NHS centers to be constructed in London ... book the equipment portion of the order in its fiscal ...
(Date:7/27/2015)... 27, 2015   Iagnosis , the creator ... in online dermatology solutions, announced today its 2015 ... company has contractual relationships with dermatologists in 30 ... Dermatologists and Extenders Since December 2014, ... number of providers delivering care through the platform, ...
(Date:7/27/2015)... , July 27, 2015  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, today announced ... (CTA) with Heath Canada to conduct ... d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate (NMDA) receptor ... pain. "We are very encouraged by ...
Breaking Medicine Technology:Varian Signs Contracts to Equip Two National Proton Therapy Centers in England 2Varian Signs Contracts to Equip Two National Proton Therapy Centers in England 3Varian Signs Contracts to Equip Two National Proton Therapy Centers in England 4Iagnosis Reports Significant Growth YTD 2015 2Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 2Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 3
... 16 Trubion Pharmaceuticals, Inc. (Nasdaq: ... data regarding its SCORPION(TM) multispecific therapeutic technology at ... of Cancer Research (AACR) in Denver, April 18-22, ... data demonstrating the selectivity and high potency of ...
... Agonist to Advance for Treatment of AllergySAN DIEGO , ... company focused on the development of novel Toll-Like Receptor ... and inflammatory diseases, announced today that it has initiated ... intranasal TLR8 agonist for the treatment of allergic rhinitis. ...
Cached Medicine Technology:Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting 2Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting 3VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis 2
(Date:7/28/2015)... ... July 28, 2015 , ... Want to improve your ... or in your easy chair? Luckily, there are plenty of back-friendly cardio exercises that ... orthopedic spine surgeon at Atlantic Spine Center . , It’s simply untrue ...
(Date:7/27/2015)... ... July 28, 2015 , ... Almost a year ago, ... offer behavioral health counseling for persons who are obese and those who are overweight ... clear. , That mandate will affect any commercial health plan with a program year ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association of ... the NAPW VIP Woman of the Year Circle. She is recognized with this prestigious ... Local Chapters, NAPW is the nation’s leading networking organization exclusively for professional women. , ...
(Date:7/27/2015)... ... , ... The heroin epidemic is affecting the Charlotte in North Carolina equally ... rate for heroin usage has continued to climb around the country in part because ... alternative for those with an addiction to prescription opiate medications. According to WCNC, the ...
(Date:7/27/2015)... ... 27, 2015 , ... Looking to brush up on all the things you ... New Jersey has enhanced its Dental webpage with new materials, including user-friendly, educational videos, ... “Horizon is committed to offering our 3.8 million members tools and resources to help ...
Breaking Medicine News(10 mins):Health News:Safe Cardio for Back Pain Sufferers 2Health News:Safe Cardio for Back Pain Sufferers 3Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 3Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2
... of studies,School-based sexual abuse prevention programs can teach children ... ,However, the programs have a downside: they ... the review cautions. ,,It was a concern that ... review, but we were pleased that there was an ...
... every time you feel a cold starting isnt such a good ... will most probably end up getting the sniffles . ... over several decades and including more than 11,000 people who took ... ,The review, according to the researchers at the Australian National ...
... of pregnancy rumours once again when she was pictured with ... York premiere of John Travolta starrer Hairspray dressed in a ... reports the Daily Mail. ,Holmes sparked off rumours ... child when she was spotted with bump while visiting new ...
... Sreemathi Wednesday said the government was not averse to inviting ... of a mosquito borne fever in the state that has ... different expert teams have arrived in the state since the ... reports, which have confirmed the fever as chikunguniya and nothing ...
... reserved seats for students suffering from AIDS and cancer in ... reserved one seat for each of the fifty-six courses that ... cancer. ,However, the university feels that one seat ... being, since it do not expects many patients queuing up ...
... that set out to assess the effectiveness and tolerability ... methods of contraception found that they were all good ... implant was found to be any more or less ... ,,The most common side effect with all the implants ...
Cached Medicine News:Health News:School-based Sexual Abuse Prevention Programs 2Health News:School-based Sexual Abuse Prevention Programs 3
This design features a solid red iris....
This camouflaging lens features the solid black stripes of the lightning fast African zebra, on a white iris background....
Sphere Introducer...
Reusable cannula with .90 mm (20 g) shaft, tapering to .30 mm (30 g). Angled 125 3 mm from tip and flattened for easy insertion into the subretinal space....
Medicine Products: